These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
402 related items for PubMed ID: 17166333
1. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group. Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333 [Abstract] [Full Text] [Related]
2. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [Abstract] [Full Text] [Related]
3. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Kwan JT, Pratt RD, Epoetin Delta Study Group. Curr Med Res Opin; 2007 Feb; 23(2):307-11. PubMed ID: 17288685 [Abstract] [Full Text] [Related]
5. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators. Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476 [Abstract] [Full Text] [Related]
10. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593 [Abstract] [Full Text] [Related]
11. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Jacobs C, Frei D, Perkins AC. Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128 [Abstract] [Full Text] [Related]
12. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828 [Abstract] [Full Text] [Related]
13. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. Milutinović S, Plavljanić E, Trkulja V. Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421 [Abstract] [Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS. Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233 [Abstract] [Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Smith WB, Dowell JA, Pratt RD. Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688 [Abstract] [Full Text] [Related]